Short Term Rating on Novadaq Technologies Inc (NVDQ)

Novadaq Technologies Inc (NVDQ) : The consensus on Novadaq Technologies Inc (NVDQ) based on 9 analyst recommendation on the company stock is 1.56, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Novadaq Technologies Inc (NVDQ) : The most positive equity analysts on Novadaq Technologies Inc (NVDQ) expects the shares to touch $17, whereas, the least positive believes that the stock will trade at $7 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $14.69 with an expected fluctuation of $3.37 from the mean.

For the current week, the company shares have a recommendation consensus of Buy.


Novadaq Technologies Inc (NASDAQ:NVDQ): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.04 and $8.96 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.16. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.06, notching a gain of 0.55% for the day. The total traded volume was 1,022,794 . The stock had closed at $9.01 on the previous day.

Novadaq Technologies Inc. develops and commercializes medical imaging and therapeutic devices for use in the operating room. The Companys imaging platform can be used to visualize blood vessels, nerves and the lymphatic system during surgical procedures. The Company generates revenues from the sale of medical devices and consumables, capital devices or consumable products, the rental of capital devices, royalties, upfront payments received from partners for exclusive sales and marketing rights, and extended warranty services agreements in connection with capital sales. The Companys SPY imaging products are SPY Elite, FIREFLY, LUNA, PINPOINT, CO2 HEART LASER systems and DermACELL Advanced Decellularized Dermis. The SPY Imaging System is United States Food and Drug Administration (FDA) cleared for use in seven surgical specialties, including coronary artery bypass, cardiovascular, plastic, reconstructive, micro, organ transplant and gastrointestinal surgery.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.